{"id":334302,"date":"2020-05-08T00:00:00","date_gmt":"2020-05-07T22:00:00","guid":{"rendered":"https:\/\/medizinonline.com\/head-to-head-study-delivers-exciting-results\/"},"modified":"2020-05-08T00:00:00","modified_gmt":"2020-05-07T22:00:00","slug":"head-to-head-study-delivers-exciting-results","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/en\/head-to-head-study-delivers-exciting-results\/","title":{"rendered":"Head-to-head study delivers exciting results"},"content":{"rendered":"

Interleukin-23 and interleukin-17A play an important role in the inflammatory process of plaque psoriasis. A comparison of two agents directed against these targets in moderate to severe plaque psoriasis led to interesting results.<\/strong><\/p>\n

Back to “Atopic dermatitis and psoriasis news”.<\/a><\/em><\/strong><\/span><\/p>\n

<\/p>\n

As the pharmaceutical company AbbVie Inc. in a press release, the IL23 inhibitor risankizumab (Skyrizi\u2122) [1] proved superior to the IL17A inhibitor secukinumab (Cosentyx\u00ae<\/sup>) [2] in this double-blind, randomized, active-controlled, open-label phase III multicenter study with regard to various primary and secondary endpoints after a treatment period of 52 weeks [3].  Subjects were randomized 1:1 to the Skyrizi\u2122 150 mg*<\/sup> (n=164) or Cosentyx\u00ae<\/sup> 300 mg**<\/sup> (n=163) condition as subcutaneous injections. The two primary endpoints were defined as non-inferiority at week 16 and superiority at week 52 with respect to PASI90. Secondary endpoints were the values of the following parameters at week 52: PASI 100, sPGA 0\/1, and PASI 75.<\/p>\n

 <\/p>\n

\"\"<\/p>\n

 <\/p>\n

Under treatment with risankizumab, a proportion of 74% of patients reached PASI90 at week 16, compared with only 66% in the secukinumab condition [3]. Risankizumab also met the second primary endpoint (87% PASI 90 response vs. 57% with secukinumab, p<0.001) [3]. The IL23 inhibitor risankizumab also proved superior to the IL17A inhibitor secukinumab in all measured secondary endpoints in this study, including PASI 100, PASI 75, and sPGA 0\/1 at week 52 (p<0.001) [3]. The safety profile of Skyrizi\u2122 was consistent with that of previous studies, with no new safety signals reported over the 52-week study period (4-6). The biologics Skyrizi\u2122 (risankizumab) [1] and Cosentyx\u00ae<\/sup> (secukinumab) [2] are approved in Switzerland for the treatment of moderate to severe plaque psoriasis in adults. These are two of the successively expanded spectrum of interleukin-antagonistic treatment options for psoriasis patients in recent years. The two cytokines IL-23 and IL17A differ with respect to various molecular biological characteristics (Table 1)<\/strong>.<\/p>\n

 <\/p>\n

*<\/sup>  Condition Skyrizi\u2122 150 mg: 2 subcutaneous 75 mg injections each at weeks 0, 4, and 12; thereafter at 12-week intervals.
\n**<\/sup> Condition Cosentyx\u00ae<\/sup> 300 mg: 2 subcutaneous 150 mg injections each at week 0,1,2,3,4; thereafter at 4-week intervals.<\/p>\n

Source: AbbVie Inc.<\/em><\/p>\n

\nLiterature:<\/p>\n

    \n
  1. Skyrizi [Summary of Product Characteristics]. AbbVie Ltd. Available at: www.ema.europa.eu.<\/li>\n
  2. Cosentyx: https:\/\/compendium.ch, last accessed 12.02.2020<\/li>\n
  3. AbbVie press release: https:\/\/news.abbvie.com\/news\/press-releases\/new-head-to-head-phase-3-data-show-skyrizi-risankizumab-superior-to-cosentyx-secukinumab-across-primary-and-all-ranked-secondary-endpoints-in-adults-with-moderate-to-severe-plaque-psoriasis-at-52-weeks.htm<\/li>\n
  4. Gordon K, et al: Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. The Lancet 2018;  25; 392(10148): 650-661.<\/li>\n
  5. Reich K, et al: Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. Lancet 2019; 394(10198): 576-586.<\/li>\n
  6. Blauvelt A, et al: Efficacy and Safety of Continuous Q12W Risankizumab Versus Treatment Withdrawal: 2-Year Double-Blinded Results from the Phase 3 IMMhance Trial. Poster #478. 24th World Congress of Dermatology. 2019.<\/li>\n
  7. Gooderham MJ, et al: Shifting the focus – the primary role of IL-23 in psoriasis and other inflammatory disorders. J Eur Acad Dermatol Venereol 2018; 32: 1111-1119.<\/li>\n
  8. Girolomoni G, et al: The role of IL-23 and the IL-23\/TH17 immune axis in the pathogenesis and treatment of psoriasis. J Eur Acad Dermatol Venereol 2017; 31: 1616-1626.<\/li>\n<\/ol>\n

     <\/p>\n

    DERMATOLOGIE PRAXIS 2020; 30(1): 27 (published 2\/22\/20, ahead of print).<\/em><\/p>\n

    Back to “Atopic dermatitis and psoriasis news”.<\/a><\/em><\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"

    Interleukin-23 and interleukin-17A play an important role in the inflammatory process of plaque psoriasis. A comparison of two agents directed against these targets in moderate to severe plaque psoriasis led…<\/p>\n","protected":false},"author":7,"featured_media":94813,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Biologics for psoriasis","footnotes":""},"category":[11340,11530,11323,11548,11503],"tags":[14032],"powerkit_post_featured":[],"class_list":["post-334302","post","type-post","status-publish","format-standard","has-post-thumbnail","category-dermatology-and-venereology","category-market-medicine","category-partner-content-en","category-rx-en","category-studies","tag-psoriasis-en-2","pmpro-has-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-06-25 16:40:30","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"en_US","wpml_translations":{"fr_FR":{"locale":"fr_FR","id":334196,"slug":"une-etude-tete-beche-donne-des-resultats-passionnants","post_title":"Une \u00e9tude t\u00eate-b\u00eache donne des r\u00e9sultats passionnants","href":"https:\/\/medizinonline.com\/fr\/une-etude-tete-beche-donne-des-resultats-passionnants\/"},"it_IT":{"locale":"it_IT","id":334309,"slug":"lo-studio-testa-a-testa-fornisce-risultati-entusiasmanti","post_title":"Lo studio testa a testa fornisce risultati entusiasmanti","href":"https:\/\/medizinonline.com\/it\/lo-studio-testa-a-testa-fornisce-risultati-entusiasmanti\/"},"pt_PT":{"locale":"pt_PT","id":334315,"slug":"o-estudo-frente-a-frente-fornece-resultados-empolgantes","post_title":"O estudo frente-a-frente fornece resultados empolgantes","href":"https:\/\/medizinonline.com\/pt-pt\/o-estudo-frente-a-frente-fornece-resultados-empolgantes\/"},"es_ES":{"locale":"es_ES","id":334323,"slug":"un-estudio-comparativo-arroja-resultados-apasionantes","post_title":"Un estudio comparativo arroja resultados apasionantes","href":"https:\/\/medizinonline.com\/es\/un-estudio-comparativo-arroja-resultados-apasionantes\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/334302","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/comments?post=334302"}],"version-history":[{"count":0,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/334302\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media\/94813"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media?parent=334302"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/category?post=334302"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/tags?post=334302"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/powerkit_post_featured?post=334302"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}